MHRA to review blood monitoring requirements for clozapine patients

MHRA to review blood monitoring requirements for clozapine patients

The Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing blood monitoring requirements for patients using…

Continue Reading
MHRA to review evidence of harm linked to pseudoephedrine-containing medicines

MHRA to review evidence of harm linked to pseudoephedrine-containing medicines

The Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing available evidence on potentially serious side…

Continue Reading
OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

NEW YORK, March 11, 2025–(BUSINESS WIRE)–OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies…

Continue Reading
MHRA warns of unsafe counterfeit anti-choking devices

MHRA warns of unsafe counterfeit anti-choking devices

The Medicines and Healthcare products Regulatory Agency (MHRA) is warning the public not to buy counterfeit…

Continue Reading
Update on MHRA safety review of medicines containing pseudoephedrine

Update on MHRA safety review of medicines containing pseudoephedrine

Pseudoephedrine is licensed for the symptomatic relief of nasal and sinus congestion in colds, flu, and…

Continue Reading
Outcome of MHRA review of neuropsychiatric reactions with montelukast

Outcome of MHRA review of neuropsychiatric reactions with montelukast

More prominent warnings are to be added to the leaflet that is provided with every pack…

Continue Reading